Status:
WITHDRAWN
FLT-PET Activity Change After Allogeneic Umbilical Cord Blood (UCB) Therapy in Cerebral Palsy
Lead Sponsor:
Bundang CHA Hospital
Conditions:
Cerebral Palsy
Eligibility:
All Genders
6-20 years
Phase:
PHASE2
Brief Summary
This is randomized placebo-controlled trial to recognize new cell regeneration in the brain using FLT-PET.
Detailed Description
FLT(3'-Deoxy-3'-\[F-18\]Fluorothymidine) has been developed as a cell-proliferation tracer. In animal study, FLT-PET was used as a tool that enables imaging and measuring of proliferation in the brain...
Eligibility Criteria
Inclusion
- Cerebral Palsy
- Abnormal muscle tone
- Gross Motor Function Classification System (GMFCS): I, II, III, IV, V
- Willing to comply with all study procedure
Exclusion
- Medical instability including pneumonia or renal function at enrollment
- Presence of known genetic disease
- Presence of drug hypersensitivity which is related to this study remedy
- Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up
- Decision by the principal investigator when there are unexpected events including brain surgery, that may affect the outcome
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01486732
Start Date
March 1 2013
End Date
July 1 2014
Last Update
November 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea, 463-712